Biotech | May 11, 2022
New nirsevimab data analyses reinforce efficacy against RSV
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
The production suspension impacts commercial and clinical trial supply
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
The aim is to bring patient consent tools in a digital format in addition to a paper format which is not just a need of the current times but also a way forward
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
